RT Journal Article
SR Electronic
T1 The Activin/Follistatin-axis is severely deregulated in COVID-19 and independently associated with in-hospital mortality
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.05.20184655
DO 10.1101/2020.09.05.20184655
A1 Synolaki, Evgenia
A1 Papadopoulos, Vasileios
A1 Divolis, Georgios
A1 Tsahouridou, Olga
A1 Gavriilidis, Efstratios
A1 Loli, Georgia
A1 Gavriil, Ariana
A1 Tsigalou, Christina
A1 Tziolos, Nikolaos R.
A1 Sertaridou, Eleni
A1 Kalra, Bhanu
A1 Kumar, Ajay
A1 Rafailidis, Petros
A1 Pasternack, Arja
A1 Boumpas, Dimitrios T.
A1 Germanidis, Georgios
A1 Ritvos, Olli
A1 Metallidis, Simeon
A1 Skendros, Panagiotis
A1 Sideras, Paschalis
YR 2020
UL http://medrxiv.org/content/early/2020/10/27/2020.09.05.20184655.abstract
AB Background Activins are members of the TGFβ-superfamily implicated in the pathogenesis of several immuno-inflammatory disorders. Based on our previous studies demonstrating that over-expression of Activin-A in murine lung causes pathology sharing key features of COVID-19, we hypothesized that Activins and their natural inhibitor Follistatin might be particularly relevant to COVID-19 pathophysiology.Methods Activin-A, Activin-B and Follistatin levels were retrospectively analyzed in 574 serum samples from 263 COVID-19 patients hospitalized in three independent centers, and compared with common demographic, clinical and laboratory parameters. Optimal-scaling with ridge-regression was used to screen variables and establish a prediction model.Result The Activin/Follistatin-axis was significantly deregulated during the course of COVID-19, correlated with severity and independently associated with mortality. FACT-CLINYCoD, a novel disease scoring system, adding one point for each of Follistatin>6235pg/ml, Activin-A>591pg/ml, Activin-B>249pg/ml, CRP>10.3mg/dL, LDH>427U/L, Intensive Care Unit (ICU) admission, Neutrophil/Lymphocyte-Ratio>5.6, Years of Age>61, Comorbidities>1 and D-dimers>1097ng/ml, efficiently predicted fatal outcome in an initial cohort (AUC: 0.951±0.032, p<10−6). Two independent cohorts that were used for validation indicated comparable AUC (0.958, p=0.880 and 0.924, p=0.256, respectively).Conclusions This study unravels strong link between Activin/Follistatin-axis and COVID-19 mortality and introduces FACT-CLINYCoD, a novel pathophysiology-based tool that allows dynamic prediction of disease outcome, supporting clinical decision making.Competing Interest StatementPotential conflicts of interest: Authors BK and AK are employees of Ansh Labs, which is the manufacturer of the ELISA kits used in this study. The rest of the authors declare no conflict of interest.Clinical TrialN/AFunding StatementFunding: General Secretariat of Research and Technology, Greece, Grants: CYTONET (T1EDK-00617) and EATRIS-GR (OPS5028091).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol design was approved by the Local Scientific and Ethics Committees and Institutional Review Boards of the University Hospital of Alexandroupolis (Ref. No. 803/23-09-2019 and Ref. No. 87/08-04-2020), AHEPA University Hospital of Thessaloniki (Ref. No. 1789/2020) and ATTIKON University Hospital of Athens (Ref. No. 487/3-9-2020). Patients' records were anonymized and de-identified prior to analysis so confidentiality and anonymity were assured.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript are avaliable upon request.